- Home
- MGNX vs CEE Comparison
MGNX vs CEE Comparison
Compare MGNX & CEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- CEE
- Stock Information
- Founded
- MGNX 2000
- CEE 1990
- Country
- MGNX United States
- CEE Germany
- Employees
- MGNX N/A
- CEE N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- CEE Finance Companies
- Sector
- MGNX Health Care
- CEE Finance
- Exchange
- MGNX Nasdaq
- CEE Nasdaq
- Market Cap
- MGNX 99.7M
- CEE 105.5M
- IPO Year
- MGNX 2013
- CEE N/A
- Fundamental
- Price
- MGNX $1.66
- CEE $15.65
- Analyst Decision
- MGNX Hold
- CEE
- Analyst Count
- MGNX 6
- CEE 0
- Target Price
- MGNX $3.20
- CEE N/A
- AVG Volume (30 Days)
- MGNX 819.6K
- CEE 22.0K
- Earning Date
- MGNX 11-04-2025
- CEE 01-01-0001
- Dividend Yield
- MGNX N/A
- CEE 3.86%
- EPS Growth
- MGNX N/A
- CEE N/A
- EPS
- MGNX N/A
- CEE N/A
- Revenue
- MGNX $165,495,000.00
- CEE N/A
- Revenue This Year
- MGNX N/A
- CEE N/A
- Revenue Next Year
- MGNX N/A
- CEE N/A
- P/E Ratio
- MGNX N/A
- CEE N/A
- Revenue Growth
- MGNX 303.47
- CEE N/A
- 52 Week Low
- MGNX $0.99
- CEE $7.80
- 52 Week High
- MGNX $5.10
- CEE $10.32
- Technical
- Relative Strength Index (RSI)
- MGNX 45.74
- CEE 49.93
- Support Level
- MGNX $1.82
- CEE $14.99
- Resistance Level
- MGNX $2.15
- CEE $15.93
- Average True Range (ATR)
- MGNX 0.14
- CEE 0.39
- MACD
- MGNX -0.02
- CEE 0.05
- Stochastic Oscillator
- MGNX 16.95
- CEE 63.70
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.